Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus

Phuong Nguyen
*University of Wollongong, ptvn919@uowmail.edu.au*

Haibo Yu
*University of Wollongong, hyu@uow.edu.au*

Paul Keller
*University of Wollongong, keller@uow.edu.au*

Follow this and additional works at: [https://ro.uow.edu.au/smhpapers](https://ro.uow.edu.au/smhpapers)

Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences Commons

**Recommended Citation**

Nguyen, Phuong; Yu, Haibo; and Keller, Paul, "Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus" (2014). *Faculty of Science, Medicine and Health - Papers: part A*. 1788.
[https://ro.uow.edu.au/smhpapers/1788](https://ro.uow.edu.au/smhpapers/1788)

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: research-pubs@uow.edu.au
Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus

Abstract
The recent emergence and re-emergence of alphaviruses, in particular the chikungunya virus (CHIKV), in numerous countries has invoked a worldwide threat to human health, while simultaneously generating an economic burden on affected countries. There are currently no vaccines or effective drugs available for the treatment of the CHIKV, and with few lead compounds reported, the vital medicinal chemistry is significantly more challenging. This study reports on the discovery of potential inhibitors for the nsP3 macro domain of CHIKV using molecular docking, virtual screening, and molecular dynamics simulations, as well as work done to evaluate and confirm the active site of nsP3. Virtual screening was carried out based on blind docking as well as focused docking, using the database of 1541 compounds from NCI Diversity Set II, to identify hit compounds for nsP3. The top hit compounds were further subjected to molecular dynamic simulations, yielding a greater understanding of the dynamic behavior of nsP3 and its complexes with various ligands, concurrently confirming the outcomes of docking, and establishing in silico lead compounds which target the CHIKV nsP3 enzyme.

Keywords
CMMB

Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences

Publication Details
Nguyen, P. T. V., Yu, H. & Keller, P. A. (2014). Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus. Journal of Molecular Modeling, 20 (5), 2216-1-2216-12.

This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers/1788
Discovery of in silico hits targeting the nsP3 macrodomain of chikungunya virus

Phuong T. V. Nguyen, Haibo Yu*, Paul A. Keller*
School of Chemistry, University of Wollongong, 2522 Australia
Corresponding author email: hyu@uow.edu.au (HY) and keller@uow.edu.au (PAK)

Abstract
The recent emergence and re-emergence of alphaviruses, in particular the chikungunya virus (CHIKV), in numerous countries has invoked a worldwide threat to human health, while simultaneously generating an economic burden for affected countries. There are currently no vaccines or effective drugs available for the treatment of the CHIKV, and with few lead compounds reported, the vital medicinal chemistry is significantly more challenging. This study reports on the discovery of potential inhibitors for the nsP3 macro domain of CHIKV using molecular docking, virtual screening and molecular dynamics simulations, as well as work done to evaluate and confirm the active site of nsP3. Virtual screening was carried out based on blind docking as well as focused docking, using the databases of 1541 compounds from NCI Diversity Set II, to identify hit compounds for nsP3. The top hit compounds were further subjected to molecular dynamic simulations, yielding a greater understanding of the dynamic behavior of nsP3 and its complexes with various ligands, concurrently confirming the outcomes of docking, and establishing in silico lead compounds which target the CHIKV nsP3 enzyme.

Keywords: chikungunya virus, molecular docking, virtual screening, molecular dynamics simulations, nsP3 macro domain.

Introduction
Chikungunya virus (CHIKV) is an emerging mosquito-borne arthrogenic member of the alphavirus genus from the family Togaviridae, which has caused widespread outbreaks of debilitating human disease in the last 5 years [1]. The resulting chikungunya fever (CHIKF) was first described in 1952 [2], and has been identified in nearly 40 countries. It was listed in 2008 as a US National Institute of Allergy and Infectious Diseases (NIAID) category C priority pathogen due to its high morbidity and mortality rates and thus major impact on health [3,4].

After the initial mosquito bite, symptoms of chikungunya fever infection generally start in 4–7 days, and usually occur in two phases: an acute followed by a second persistent (chronic) stage that causes disabling polyarthritis [5]. Acute infection lasts 1–10 days and is characterized by a painful polyarthralgia, high fever, asthenia (weakness), headache, vomiting, rash, and myalgia [6]. The persistent chronic stage of CHIKF is characterized by polyarthralgia lasting from weeks to years [7]. Additional symptoms include neurological disorders such as encephalitis, myeloneuropathy, peripheral neuropathy, myelopathy and myopathy [8].

The CHIKV genome consists of a single stranded, positive-sense RNA genome with two open reading frames (ORFs) [9], and is approximately 11.8 Kb in size. The ORF at the 5’ end encodes two polyproteins, the precursors of the non-structural proteins. The second ORF at the 3’ end encodes the structural proteins, the capsid (C), envelope glycoproteins E1 and E2 and two small cleavage products (E3, 6K). CHIKV starts its life cycle by entering the target host cells through pH-dependent endocytosis via a receptor-mediated interaction [10] in an analogous manner to other members of the Alphaviruses genus.

The medicinal chemistry of CHIKV has recently been reviewed [11]. That review highlighted the extreme lack of available chemotherapeutics that show any inhibitory effects against the virus. In
contrast, the emergence of numerous models and solved crystal structures of CHIKV proteins points to enormous possibilities for directed drug design. Notable among the available targets are the envelope proteins [12-15] and the non-structural proteins of CHIKV, which play an important role in the formation of the transcription/replication complex of the virus [15,16]. Among these, nsP3 is considered an attractive target for drug design because of its participation in the early stage of the transcription process of viral replication, even though the specific functions, roles, and activities of the nsP3 protein remain elusive [16,17].

To date, there have been relatively few studies on the functions, roles and activities of alphavirus nsP3 proteins [11,18-20]. Studies based on the Sindbis virus reported that nsP3 phosphoprotein is an essential component of the viral replication and transcription process. Functional analysis of the effects of mutations of nsP3 on the RNA synthesis demonstrated that the mutations can cause a loss of capacity for minus-strand synthesis or a failure to increase plus-strand synthesis. Strikingly, a change in G4303 implying an alteration from Gly to Ala68 and leading to a modification to the His-Ala-Val peptide was predicted to form part of the active site of the conserved nsP3 macro domain [19]. However, no effect of the mutations on the ADP-ribose binding site was found [17]. The nsP3 protein consists of two domains, the N-domain and the C-domain [16,17]; the N-domain is highly conserved but the C-domain is not [17]. The C-domain is phosphorylated at up to 16 positions on serines and threonines [11,17]. The role of this phosphorylation is still not clear, but deletion of the residues involved in the phosphorylated process can decrease the level of RNA synthesis [11,17,21]. The N-domain, in which the region comprising the first 160 residues is called the X-domain or a macro domain, is commonly present in eukaryotic organisms, bacteria, archaea and in many positive-strand RNA viruses such as hepatitis E, rubella, coronavirus and alphaviruses [16]. The alphavirus macro domain has a highly positive charged patch on the surface of the protein at the crevice of ADP-ribose 1\(^{-}\)-phosphate active site and its periphery [17]. The other side of the protein, far from the active site, possesses a negative charge. Thus, the nsP3 macro domain is considered to complex with ADP-ribose derivatives and RNA. It is also believed to control the metabolism of ADP-ribose 1\(^{-}\)-phosphate and/or other ADP-ribose derivatives with regulatory functions in the cell [11,22].

The crystal structure of the nsP3 macro domain of CHIKV was solved in 2010 [17]. The asymmetric unit of CHIKV includes four molecules. The macro domain consists of six-stranded \(\beta\)-sheets and four \(\alpha\)-helices, and the positions of the \(\alpha\)-helices are highly conserved. Also present is the ligand ADP-ribose, and the active site of nsP3 macro domain is considered the binding site for this ADP-ribose ligand [16,17]. This crevice is at the top of the \(\beta\)-strands 2, 4 and 5 and is surrounded by two loops between \(\beta2-\alpha1\) and \(\beta5-\alpha3\). Since there is very little information available on the nsP3 macro domain and its inhibitor, the current study used computational approaches (including molecular docking and virtual screening) to discover potential compounds that inhibit nsP3 in CHIKV. Furthermore, in order to understand both the static structures and the dynamic information, molecular dynamics simulations were performed to gain a greater understanding of the behavior of nsP3 and how it changes upon the binding of small molecules. The results of the study were analyzed and compared with previous data to gain a deeper understanding of the atomic structure of the nsP3 macro domain and its complexes, as well as to confirm the interactions and results from docking.

**Material and methods**

Molecular docking and virtual screening

Molecular docking and virtual screening were conducted using AutoDock Vina (version 1.5.4) [23]. In the current study, the protein was treated rigid while the ligands were fully flexible. The protein was prepared by retrieving the 3D crystal structure of the nsP3 macro domain protein from the
Protein Data Bank (PDB id: 3GPG) and this was used as the receptor for docking. The ligand ADP-ribose was extracted from the complex crystal structure (PDB id: 3GPO) whereas other ligands employed for virtual screening were downloaded from the website of the Diversity Set II chemical library of the National Cancer Institute (NCI). This library was selected as it contains diverse drug-like compounds and potential hits can be ordered from the Open Chemical Repository Collection for activity testing. The protein was subsequently minimized by applying the CHARMM force field in the Accelrys Discovery Studio 2.0 software package [24]. The steepest-descent algorithm with 3,000 steps was used to relax the structure and remove steric overlaps. With a Cu RMSD of 0.59 Å between the minimized structure and the X-ray structure, the minimized structure was utilized for the docking process. Polar hydrogen atoms were added and the Kollman charges were defined with AutoDock Tools (version 1.5.4). The key docking parameters include the location of the docking site (center x, y, z) and the size of the grid box. The docking protocol was established by re-docking the ADP-ribose into nsP3 as seen in the co-crystal structure (3GPO). In the docking with ADP-ribose, box dimensions of 16x16x16 Å was used, centered at the crystallographically determined binding site. In virtual screening, the location and the size of the grid box were carefully investigated via blind docking (in which the box is sufficiently large to cover the whole protein) and focused docking (in which a smaller box was centered on the potential binding site of interest). Blind docking can reveal potential binding sites in nsP3, but it can also suffer convergence problems during sampling. The MetaPocket program was also used to predict potential binding sites of nsP3 other than the active site [25]. After docking, the results were analyzed and compared with available experimental data. The top ten compounds (“hit”) were identified according to their binding affinities using the default scoring function in Vina. The modes of interaction between the ligands and the protein were analyzed in Accelrys Discovery Studio 2.0. The drug-like properties of these compounds were subsequently evaluated using the Lipinski Guidelines [26].

Molecular dynamics simulations of the docked complexes

In order to evaluate the stability of the docked complex and better characterize the ligand-nsP3 interactions, equilibrium molecular dynamics (MD) simulations were carried out with the NAMD package [27]. The protein atoms were treated with the CHARMM22 force field [28], and the corresponding parameters for the ligands were generated with AmberTools [29]. MD simulations were carried out for the apo state (PDB id: 3GPG) and the five ligand-nsP3 complexes. The systems were solvated in a cubic box of TIP3P water molecules and neutralized by sodium counterions to achieve the physiological ionic concentration of 0.15 M with NaCl. The total number of atoms (including protein, water and counterions) in the CHIKV system was about 18,000, and the size of water box was about 58×58×58 Å. All simulations were performed under the periodic boundary conditions at a temperature of 298.15 K and a pressure of 1 atm. Temperature and pressure coupling were maintained with the Langevin algorithm. A particle mesh Ewald algorithm was used to calculate the electrostatic interactions [30]. The cutoff distance for van der Waals interactions and the pairlist distance were 12 and 13.5 Å, respectively. The systems were minimized and then equilibrium simulations with weak harmonic restraints on the heavy atoms were performed for 3 ns. The production runs were continued for 20 ns. The trajectories were saved every 1 ps. The resulting trajectories were analyzed using the CHARMM [31] and VMD 1.9 programs [32].

Results

Validation of the docking protocol by re-docking with ADP-ribose

The docking protocol was evaluated by re-docking ADP-ribose into nsP3, and the outcome was compared with the available co-crystal structure (PDB id: 3GPO). The ligand conformations were ranked in terms of their predicted binding affinities using the default scoring function in Vina (see
Table S1 of the “Electronic supplementary material,” ESM). The best-docked pose had a binding affinity of -10.2 kcal mol\(^{-1}\). The hydrogen bonds formed between ADP-ribose and nsP3 are shown in Fig. 1. It is evident that there were interactions with 11 residues in the active site of nsP3: Ile11, Ala23, Asn24, Asp31, Val33, Leu108, Gly112, Val113, Tyr114, Tyr142 and Arg144. Most of the hydrogen-bond donors came from the protein residues, with the corresponding acceptors deriving from the ADP-ribose. In addition, the diphosphate component of ADP-ribose showed the strongest interaction of any part of this ligand.

Moreover, the accuracy and reliability of docking was evaluated by superimposing the docked structure on the co-crystal structure. The heavy-atom root mean square deviation (RMSD) was 0.6 Å, smaller than the 2.0 Å often used as a criterion in correct bound structure prediction [33] (Table S1 of the ESM and Fig. 2) indicating that the molecular docking reproduced the binding mode in the co-crystal structure. Comparison of the interactions indicated by the docking results with published data (Table 1) confirmed there was good agreement in the key interactions and showed that this docking protocol was able to reproduce the correct pose (Fig. 2).

Identification of potential inhibitors using virtual screening

In an effort to identify potential inhibitors (hit compounds), 1541 compounds in NCI Diversity Set II were screened by docking them with the nsP3 of CHIKV. Virtual screening (VST) was carried out using three different setups. The first was a focused docking centered around the ADP-ribose binding site (pocket 1: VST1 and VST2). The second setup was a blind docking centered either at the middle of the ADP-ribose binding site (VST3) or the protein (VST4) with the box made large enough to cover the whole protein. The third setup was a focused docking centered on the binding sites predicted by MetaPocket (pocket 2: VST5; pocket 3: VST6). The top ten compounds for each VST based on their binding affinities are listed in Table S2 of the ESM.

In the focused dockings that targeted binding pocket 1 (the ADP-ribose binding site; VST1 and VST2), the top hits were NCI_25457 (-10.8 kcal mol\(^{-1}\)) and NCI_345647_a (-10.9 kcal mol\(^{-1}\)). Among the top ten hits, four are shared between VST1 and VST2, which differ in the size of the grid box used. Given our interest in finding more inhibitors as well as other potential binding sites in the structure of nsP3, we used the blind docking to dock into the entire protein, with the grid box centered on the middle of either the ADP-ribose binding site (VST3) or the protein (VST4). For the blind docking (VST3 and VST4), six of the top ten hits are common to VST3 and VST4, and the binding affinities were reproduced to within 1.0 kcal mol\(^{-1}\). This indicates that the blind dockings are likely to have converged. The results show that most of the top ten hits fitted well in pocket 1, and this pocket can accommodate ligands of different sizes. However, ligands having bulky structures, such as NCI_293778, NCI_58052 and NCI_61610 (common to the top ten hits of both VST3 and VST4), protruded from the binding site. Furthermore, the other pockets surrounding pocket 1 may serve as alternative binding sites for potential inhibitors.

By comparing the results from the blind dockings with the pockets predicted for nsP3 using MetaPocket, pocket 2 and pocket 3 were identified, and focused docking at pockets 2 (VST5) and 3 (VST6) was conducted. Screening at VST5 and VST6 produced hits that had already been identified in previous screens, along with some new hits (Table S2 of the ESM). Pockets 1 and 3 share a number of interacting residues, including Asn24, Asp31, Val33, Gly112, Val113 and Tyr114. In contrast, pocket 2 was located on the opposite side and behind pocket 1, and comprised the residues His1, Pro2, Ser3, Tyr4, Met132, Asp133, Ser134, Thr135, Asp136, Ala137, Asp138, Val139, Arg159, Thr160, Ile156 and Gln157. The location of the pockets in nsP3 and the location of the different ligands in the three pockets are illustrated in Figs. 3 and 4. Most of compounds effectively occupy pockets 2 and 3 and participate in significant interactions. Ligands NCI_127133 (-8.3 kcal mol\(^{-1}\)) and NCI_670283 (-10.6 kcal mol\(^{-1}\)) bind in pockets 2 and 3 as well as pocket 1, but
in different conformations. Interestingly, the ligand NCI_293778 would be able to bind into all three pockets, although it may be inferred that the pocket 1 is more favorable for binding, with a binding affinity of -10.5 kcal mol\(^{-1}\) compared to -9.4 kcal mol\(^{-1}\) (pocket 3) and -8.3 kcal mol\(^{-1}\) (pocket 2).

For the virtual screening, it is worth mentioning that the changes in size of the grid box and its location affected the search process in Vina. Increasing the dimensions of the box is likely to be better suited to larger molecules. For instance, in the blind docking (VST3 and VST4), NCI_61610 (\(-11.1\) kcal mol\(^{-1}\)) was identified as a top ten hit, but it is not one of the top ten hits for VST1 and VST2. The locations of the three binding sites along with the top five compounds obtained from VST are displayed in detail in Fig. 3 (for more information, see Fig. S1 of the ESM). It is also interesting that the majority of the hit compounds show tighter binding in pocket 1 than in pocket 2. Detailed analyses of the interactions between the ligands and protein target were carried out by characterizing the hydrogen bonds and hydrophobic contacts [34]. The results show that hydrogen-bonding interactions play a more important role in the binding to pocket 1, whereas hydrophobic contacts are responsible for the interactions associated with the binding to pocket 2. In agreement with this, it was previously reported [16] that the residues Ser110, Thr111, Gly112 and Tyr114 define pocket 1 and are key residues in interactions with ligands. In addition, we found that these residues also define pocket 3.

Investigation into the stability of the protein and its complex using molecular dynamics simulations

The top five hit compounds NCI_61610, NCI_25457, NCI_345647_a, NCI_670283 and NCI_127133 from each screening were subsequently subjected to molecular dynamics simulations (Table 2). MD simulations were undertaken to investigate the dynamic behaviors of protein nsP3 and its complexes and to obtain the precise binding modes [35]. MD simulations were carried out with the NAMD package with the CHARMM force field for 20 ns following 3 ns of equilibrium simulations.

In order to assess the overall stability, RMSD values with respect to the starting structure were used as the major criterion. The backbone RMSD curves for nsP3 and its complexes with different ligands with respect to the starting structure were not significantly different from each other (Fig. 5). All systems were relatively stable throughout the simulations after reaching equilibrium within 3 ns. Hence, data taken from the trajectories in the last 20 ns will be used for further analysis.

The root mean square fluctuation (RMSF) of the Cα atoms of each residue was calculated using the data from 20-ns trajectories of the protein nsP3 and its complexes (Fig. 6). The RMSF profiles of the apoprotein and the complexes were similar. However, subtle differences were observed for a few regions, including the loop at residues 31-34. The residues comprising the binding pockets were quite stable during the simulations, with fluctuation of < 1.0 Å. It is worth noting that when the three ligands NCI_61610, NCI_25457 and NCI_345647_a were bound to the protein at pocket 1, the RMSFs for the binding loop region 31-34 were noticeably smaller than those seen for the apoprotein. The RMSF for this loop was not significantly perturbed when the ligands NCI_670283 and NCI_127133 were bound to pockets 3 and 2, respectively.

Interaction between the ligands and the protein nsP3

A detailed analysis of the hydrogen-bonding (H-bond) interactions and hydrophobic contacts between the ligands and nsP3 was carried out. Simple geometric criteria were used to define a hydrogen bond: a distance between proton donor (D) and acceptor (A) atoms of <3.5 Å and an angle D-H…A of >120° [16]. If the H-bond occupation percentage was >50%, they were considered to arise from the medium, whereas strong hydrogen bonds are considered to be present
for H-bond occupations of greater than 75% [16]. Hydrophobic contacts between the carbon atoms of non-polar parts of protein residues were also monitored, with a cutoff distance of 4.0 Å assumed [36,37].

Complementary to the results of the docking (where the protein was kept rigid), molecular dynamics simulations revealed that when the ligands bind to nsP3, the ligand or/and the residues in the binding pockets fluctuate, with the residues adapting their structures to better accommodate the ligands by forming H-bonds and/or hydrophobic contacts. This can be illustrated by superimposing the complex before the simulations (at 0 ns) on the complex after the simulation (at 23 ns); see Fig. 7. Not surprisingly, the figure shows that some residues, such as Val33, Val113, Tyr114, Arg144 and Trp148 (for ligands binding to the pocket 1; see Fig. 7a, 7b and 7c), display noticeable movement upon binding. For ligands NCI_127133 (pocket 2) and NCI_670283 (pocket 3), the results showed that the fluctuations of residues Ala1, Pro2 and Tyr4 (in the pocket 2) and residues Ala22, Val33, Val113 and Tyr114 (pocket 3) were required for a correct fit into nsP3.

Key residues forming hydrogen bonds and hydrophobic contacts between nsP3 and ligands

Hydrogen-bonding analyses revealed that the binding of each investigated ligand to the protein is stabilized by a number of hydrogen bonds, except ligand NCI_127133 (Table 3). We can infer that the binding site at pocket 1, where NCI_61610, NCI_25457 and NCI_345647_a bind, is the most favorable place for ligands to form hydrogen bonds (Fig. 8). There are three strong hydrogen bonds between ligand NCI_61610 and residue Asn24 (98%), Tyr114 (92%) and Gly112 (88%) in pocket 1, but only one strong and one moderately hydrogen bond between NCI_670283 and Thr111 (78%) and Gly112 (66%) in the pocket 2 (Fig. 7). In contrast, pocket 3 is unlikely to be favored for binding, as no H-bonds with occupations of >10% were identified.

Furthermore, the residues in the region 110-114 of the protein are key residues that are responsible for forming the hydrogen bonds between the protein and the ligands in binding pockets 1 and 3. Most of them serve as hydrogen bond donors, except in the complex nsP3-NCI_61610, where residue Thr111 serves as an acceptor. This observation is in close agreement with the results of earlier simulations and experimental data [16]. In addition, it emerged that the structures of NCI_61610 and NCI_345647_a are more polar than the other ligands, so more hydrogens bonds were found in complexes involving them than in complexes involving the other ligands.

The nsP3 residues that were found to interact with the ligands through hydrophobic contacts are listed in Table 4. It is worth noting that four residues, namely Val33, Val113, Tyr114 and Trp148, play a crucial role in stabilizing the complexes by facilitating hydrophobic interactions between the ligands and nsP3 at the binding pockets 1 and 3, while Ala1, Pro2 and Tyr4 are important in pocket 2. The solvent accessible surface areas (SASA) were calculated to monitor the possible changes in the salvation environment upon ligand binding (Table 5). We expected to see that the SASA for hydrophobically interacting residues in the protein-ligand complex will decrease compared to those in apoprotein. In pocket 1, when the ligands bind to protein, it can be seen that the solvent surface of residue Tyr114 decreases from 70.2 Å² in the apo nsP3 to 63.4 Å² for the nsP3-NCI_61610 complex and 63.8 Å² for nsP3-NCI_345647_a complex. Also, the SASA of Val33 reduces from 68.8 Å² in the apo state to 57.4 Å² and 52.9 Å² for the bound state in nsP3-NCI_25457 and NCI_345647_a, respectively. However, it is apparent that the changes in SASA for Val33, Val113 and Trp148 are not consistent for different ligands. This can be rationalized by noting that these residues are able to form not only hydrophobic contacts but also polar hydrogen-bonding interactions. Thus, the change in SASA is compromised by polar interactions, and both types of interaction modulate the SASA.
In order to probe the effects of the static protein structure used in the docking, multiple docking simulations and virtual screening were carried out based on the sampled conformations of protein nsP3-NCI_61610 at different simulations times (5, 10, 15, and 20 ns). These results are listed in Tables S3 and S4 of the ESM. The binding affinities observed in these docking runs (Table S3 of ESM) were not significantly different from those obtained in previous dockings based on the X-ray structure. Additionally, the binding modes observed in the dockings based on the X-ray structure are similar to those obtained based on the MD sampled structures. Most of the top hits in the virtual screening were the same compounds as those identified in the previous screening, although there were some new hits too. This indicates that the docking results were similar for different static structures of the nsP3 protein.

**Discussion and conclusion**

So far, little information on the nsP3 macro domain and its inhibitors has been reported. The present study is of great importance in relation to identifying novel inhibitors of the chikungunya virus. It is also the first to combine molecular docking, virtual screening and molecular dynamics simulations to identify potential inhibitors that target CHIKV by taking advantage of the recently determined high-resolution crystal structure of nsP3 in complex with ADP-ribose. Considering the presence of positive charge at the ADP-ribose binding site, this binding pocket may have the tendency to accommodate negatively charged ligands, which may not have acceptable pharmacokinetic properties. Therefore, we decided to identify all possible binding pockets based on the available methods. We first re-docked the ADP-ribose and successfully reproduced the bound structure and the key residues for interactions in the ADP ribose binding pocket. It was evident that the binding affinity of ADP-ribose was less than -10 kcal mol⁻¹, showing that this negatively-charged ligand binds very tightly to nsP3. This study also demonstrates that the current docking protocol utilizing Autodock Vina is a robust approach for reproducing experimentally determined binding modes.

Subsequently, virtual screening with the NCI Diversity Set II was undertaken to identify potential novel inhibitors that target CHIKV. In addition to the well-characterized adenine binding pocket (pocket 1), two additional binding pockets (pockets 2 and 3) were identified through blind docking and using MetaPocket. Pocket 3 partially overlapped with pocket 1, while pocket 2 was located on the opposite side of the protein (Fig. 3). A comparison of the binding affinities at the three different binding pockets revealed that all of the hits for pocket 1 bind to the protein well, with binding affinities of less than -10 kcal mol⁻¹. This suggests that the pocket 1 is the most favorable for ligand binding. In contrast, pocket 2 may not be a good location for binding compared to pockets 1 and 3 because it is associated with higher binding affinities. It is also interesting to note that some ligands were repeated multiple times in the list of virtual screening results. These ligands can bind to different pockets in different conformations (e.g.; the ligand NCI_127133 binds to pockets 1 and 2, ligand NCI_670283 binds to pockets 1 and 3 and ligand NCI_293778 binds to pockets 1, 2 and 3). These ligands may therefore have greater potential for use as inhibitors.

By analyzing the hydrogen bonding and hydrophobic interactions between the ligands and nsP3, key residues were identified. The region encompassing residues 110-114 was predicted to be the most important area for ligands interactions. This is consistent with the results of previous work by Rungrotmongkol et al. [16].

Furthermore, equilibrium molecular dynamics simulations were carried out to validate the molecular docking results. Analysis of the simulations confirmed that the docked ligand-nsP3 complexes were stable during the 20-ns simulation. However, subtle structural rearrangements in nsP3 were observed that led to better accommodation of the ligands. MD simulations also confirmed that the binding pocket 1 is the favored pocket for ligand binding, considering the favorability of the interactions between the ligands and nsP3.
In summary, through a combination of molecular docking, virtual screening and molecular dynamics simulations, we identified potential inhibitors of CHIKV based on the targeting of its nsP3 macro domain. In the future work, the detailed binding modes for the identified inhibitors will be better characterized by performing more computationally extensive free-energy calculations, and their inhibitory effects will be verified by experimental studies. Additionally, the present work provides useful information for constructing pharmacophores in ligand-based drug design and for generating the chemical libraries utilized in the development of novel inhibitors targeting CHIKV.

Acknowledgements
This project was funded by a University of Wollongong UOW-Vietnamese Government Scholarship (VIED-MOET). H.Y. is the recipient of an Australian Research Council Future Fellowship (Project number FT110100034). This research was undertaken with the assistance of resources provided by the University of Wollongong High Performance Computing Cluster.

Reference
1. Her Z, Kam Y-W, Lin RTP, Ng LFP (2009) Chikungunya: a bending reality. Microbes Infect 11 (14-15):1165-1176. doi:10.1016/j.micinf.2009.09.004
2. Robinson MC (1955) An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. T Roy Soc Trop Med H 49 (1):28. doi:10.1016/0035-9203(55)90080-8
3. Powers AM, Logue CH (2007) Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88 (Pt 9):2363-2377. doi:10.1099/vir.0.82858-0
4. Schwartz O, Albert ML (2010) Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol 8 (7):491-500. doi:10.1038/nrmicro2368
5. Ziegler SA, Lu L, da Rosa AP, Xiao SY, Tesh RB (2008) An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg 79 (1):133-139. doi:79/1/133 [pii]
6. Queyriaux B, Simon F, Grandadam M, Michel R, Tolou H, Boutin J-P (2008) Clinical burden of chikungunya virus infection. Lancet Infect Dis 8 (1):2-3. doi:10.1016/s1473-3099(07)70294-3
7. Santhosh SR, Dash PK, Parida MM, Khan M, Tiwari M, Lakshmana Rao PV (2008) Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res 135 (1):36-41. doi:10.1016/j.virusres.2008.02.004
8. Chandak NH, Kashyap RS, Kabra D, Karandikar P, Saha SS, Morey SH, Purohit HJ, Taori GM, Daganwala HF (2009) Neurological complications of Chikungunya virus infection. Neurology India 57 (2):177-180. doi:10.4103/0028-3886.51289
9. Singh SK, Unni SK (2011) Chikungunya virus: host pathogen interaction. Rev Med Virol 21 (2):78-88. doi:10.1002/rmv.681
10. Sourisseau M, Fsihi H, Frenkiel M-P, Blanchet F, Afonso PV, Ceccaldi P-E, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Schile C, Saib A, Rey FA, Arenzana-Seisdedos F, Després P, Michault A, Albert ML, Schwartz O, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost M-C (2007) Characterization of reemerging chikungunya virus. Plos Pathog 3 (6):e89-e89. doi:10.1371/journal.ppat.0030089
11. Rashad AA, Mahalingam S, Keller PA (2013) Chikungunya Virus: Emerging Targets and New Opportunities for Medicinal Chemistry. J Med Chem. doi:10.1021/jm400460d
12. Rashad AA, Keller PA (2013) Structure based design towards the identification of novel binding sites and inhibitors for the chikungunya virus envelope proteins. J Mol Graph Modell 44:241-252. doi:10.1016/j.jmgm.2013.07.001
13. Voss J, Vaney MC, Duquerroy S, Vonrhein C, Ginard-Blanc C, Crublet E, Thompson A, Bricogne G, Rey FA (2010) Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468 (7324):709-712. doi:10.1038/nature09555

14. Singh KD, Kirubakaran P, Nagarajan S, Sakkiah S, Muthusamy K, Velmurgan D, Jeyakanthan J (2012) Homology modeling, molecular dynamics, e-pharmacophore mapping and docking study of Chikungunya virus nsP2 protease. J Mol Model 18 (1):39-51. doi:10.1007/s00894-011-1018-3

15. Gould EA, Delogu I, Forrester N, Khasnatinov M, Gritsun T, de Lamballerie X, Canard B, Coutard B, Malet H, Morin B, Jamal S, Weaver S, Gorbalenya A, Moureau G, Baronti C (2010) Understanding the alphaviruses: Recent progress on important emerging pathogens and progress towards their control. Antiviral Res 87 (2):111-124. doi:10.1016/j.antiviral.2009.07.007

16. Rungrotmongkol T, Nunthaboot N, Malaisree M, Kaiyawet N, Yotmanee P, Meeprasert A, Hannongbua S (2010) Molecular insight into the specific binding of ADP-ribose to the nsP3 macro domains of chikungunya and venezuelan equine encephalitis viruses: Molecular dynamics simulations and free energy calculations. Journal of Molecular Graphics and Modelling 29 (3):347-353. doi:10.1016/j.jmgm.2010.09.010

17. Malet H, Lafitte D, Ferron F, Lescar J, Gorbalenya AE, de Lamballerie X, Canard B, Coutard B, Jamal S, Dutartre H, Papageorgiou N, Neuvonen M, Ahola T, Forrester N, Gould EA (2009) The crystal structures of Chikungunya and Venezuelan equine encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. J Virol 83 (13):6534. doi:10.1128/JVI.00189-09

18. Lastarza MW, Lemm JA, Rice CM (1994) Genetic analysis of the nsP3 region of Sindbis virus: evidence for roles in minus-strand and subgenomic RNA synthesis. J Virol 68 (9):5781-5791

19. Dé I, Fata-Hartley C, Sawicki SG, Sawicki DL (2003) Functional analysis of nsP3 phosphoprotein mutants of Sindbis virus. J Virol 77 (24):13106-13116. doi:10.1128/jvi.77.24.13106-13116.2003

20. Wang YF, Sawicki SG, Sawicki DL (1994) Alphavirus nsP3 functions to form replication complexes transcribing negative-strand RNA. J Virol 68 (10):6466-6475

21. Lastarza MW, Grakoui A, Rice CM (1994) Deletion and Duplication Mutations in the C-Terminal Nonconserved Region of Sindbis Virus nsP3: Effects on Phosphorylation and on Virus Replication in Vertebrate and Invertebrate Cells. Virology 202 (1):224-232. doi:10.1006/viro.1994.1338

22. Neuvonen M, Ahola T (2009) Differential Activities of Cellular and Viral Macro Domain Proteins in Binding of ADP-Ribose Metabolites. Journal of Molecular Biology 385 (1):212-225. doi:10.1016/j.jmb.2008.10.045

23. Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31 (2):455-461. doi:10.1002/jcc.21334

24. Accelrys Software Inc (2013) Discovery Studio Modeling Environment. 4.0 edn. Accelrys Software Inc., San Diego

25. Huang B (2009) MetaPocket: a meta approach to improve protein ligand binding site prediction. Omics 13 (4):325-330. doi:10.1089/omi.2009.0045

26. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 46:3-26. doi:10.1016/s0169-409x(96)00423-1

27. Phillips JC, Schulten K, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26 (16):1781-1802. doi:10.1002/jcc.20289

28. MacKerell AD, Ha S, Joseph-McCarthy D, Kuchmir L, Kuczerka K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Bashford D, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M, Bellott, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H (1998) All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. J Phys Chem B 102 (18):3586-3616. doi:10.1021/jp973084f
29. Case DA, Woods RJ, Cheatham rTE, Darden T, Gohlke H, Luo R, Merz JKM, Onufriev A, Simmerling C, Wang B (2005) The Amber biomolecular simulation programs. J Comput Chem 26 (16):1668-1688. doi:10.1002/jcc.20290

30. Ulrich E, Lalith P, Max LB, Tom D, Hsing L, Lee GP (1995) A smooth particle mesh Ewald method. J Chem Phys 103 (19):8577-8593. doi:10.1063/1.470117

31. Brooks BR, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Brooks rCL, Kuczer aK, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Mackerell JAD, Venable RM, Woodcock HL, Wu X, Yang W, York DM, Karplus M, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30 (10):1545-1614. doi:10.1002/jcc.21287

32. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph Modell 14 (1):33-38. doi:10.1016/0263-7855(96)00018-5

33. Trott O, Olson AJ (2010) Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. J Comput Chem 31 (2):455-461. doi:10.1002/jcc.21334

34. Badrinarayan P, Sastry GN (2011) Virtual high throughput screening in new lead identification. Combinatorial chemistry & high throughput screening 14 (10):840-860. doi:10.2174/138620711797537102

35. van Gunsteren WF, Hünlenberger PH, Kastenholz MA, Oostenbrink C, Schenk M, Trzesniak D, van der Vegt NFA, Yu HB, Bakowies D, Baron R, Chandrasekhar I, Christen M, Daura X, Gee P, Geerke DP, Glättli A (2006) Biomolecular modeling: Goals, problems, perspectives. Angewandte Chemie (Int Ed Eng) 45 (25):4064-4092. doi:10.1002/anie.200502655

36. Bruno A, Guadix AE, Costantino G (2009) Molecular dynamics simulation of the heterodimeric mGluR2/5HT(2A) complex. An atomistic resolution study of a potential new target in psychiatric conditions. J Chem Inf Model 49 (6):1602-1616. doi:10.1021/ci900067g

37. Rajgaria R, McAllister SR, Floudas CA (2009) Towards accurate residue-residue hydrophobic contact prediction for alpha helical proteins via integer linear optimization. Proteins 74 (4):929-947. doi:10.1002/prot.22202
Figure 1. Re-docking ADP-ribose into the active site of nsP3: (A) The best docking pose of ligand ADP-ribose is represented as a stick model (colored by atom type) while the protein nsP3 is shown in the solvent surface (colored by interpolated charge with a probe radius of 1.4 Å). (B) The interactions of this pose and nsP3 residues showing hydrogen bonding interactions at the binding site of nsP3.
Figure 2. Superimposition of the ADP-ribose after docking (in red, the top pose) on its structure in the co-crystal structure (in blue) at the active site of nsP3. The heavy-atom RMSD between them is about 0.6 Å.

Figure 3. Representation of three binding pockets identified in the nsP3: (A) The location of three pockets in the nsP3. (B) Illustration of three pockets showing the locations of five top-hit compounds obtained from virtual screenings at these binding sites: NCI_25457, NCI_345647_a, NCI_61610 (in magenta) at the pocket 1, NCI_127133 (in blue) at the pocket 2 and NCI_670283 (in yellow) at the pocket 3.
Figure 4. Illustration of three binding pockets identified in the nsP3. Each illustration contains two images: the first shows the protein nsP3 (in red) as a ribbon and the ligand (in green) in stick representation, and the second shows the surface of the pocket (in purple) surrounding the bound ligand (in green) in stick representation: (A) Pocket 1 with the complex nsP3-NCI_61610. (B) Pocket 2 with the complex nsP3-NCI_127133 (structure has been rotated 180°). (C) Pocket 3 with complex nsP3-NCI_670283.
Figure 5. Backbone RMSD profiles for the apoprotein nsP3 and its complexes of nsP3 with various ligands during MD simulations.

Figure 6. RMSFs values of the Cα atoms of the apoprotein nsP3 and its different complexes, as calculated during MD simulations.
Figure 7. Superimposition of complex structures observed at 0 ns (in blue) and 23 ns (in red) with the structures represented as ribbons, the ligands as van der Waals surfaces, and the residues surrounding the ligands as sticks: (A) Apoprotein nsP3. (B)-(F): Complexes of nsP3 with the ligands NCI_61610 (B), NCI_25457 (C), NCI_345647_a (D), NCI_670283 (E), and NCI_127133 (F).
Figure 8. Hydrogen-bonding interactions between nsP3 and NCI_61610 and NCI_670283: (A) The complex of nsP3 with ligand NCI_61610 involves three strong H-bonds with residues Asn24, Tyr114 and Gly112. (B) The complex of nsP3 with ligand NCI_670283 involves one strong H-bond with Thr111 and one moderately strong H-bond with Gly112.
Table 1. Comparison of the hydrogen-bonding interactions inferred for the nsP3-ADP-ribose docked complex with previously published data. In [17], key residues were identified by performing an experimental study of the crystal structures of the complex nsP3-ADP-ribose (3GPO), while residues reported in [16] were determined by realizing molecular dynamics simulations of ADP-ribose in nsP3, based on the above crystal structures.

|                | Current work | Ref [17] | Ref [16] |
|----------------|--------------|----------|----------|
| Interacting residues | Ile11, Ala23, Asn24, Val108, Gly112, Val113, Tyr114, Tyr142, Arg144 | Asp10, Ile11, Asn24, Asp31, Thr111, Gly112, Val113, Tyr114, Tyr142, Arg144 | Asp10, Ile11, Asn24, Asp31, Val33, Ser110, Thr111, Gly112, Val113, Tyr114, Arg144 |

Table 2. Chemical structures of the top five hit compounds and their properties.

| Compound’s name | Structural formula | Binding affinities (kcal/mol) | Lipinski’s values |
|-----------------|--------------------|-------------------------------|------------------|
| 1 NCI-61610     | (C_{34}H_{24}N_{6}O_{2}) | -11.1                     | LogP: 5.31  |
|                 |                    |                              | H-D: 4       |
|                 |                    |                              | H-A: 4       |
|                 |                    |                              | MW: 548.6    |
| 2 NCI-25457     | (C_{24}H_{16}N_{2}O) | -10.8                     | LogP: 5.5    |
|                 |                    |                              | H-D: 0       |
|                 |                    |                              | H-A: 3       |
|                 |                    |                              | MW: 348.39   |
| 3 NCI-345647_a  | (C_{30}H_{26}O_{10}) | -10.9                     | LogP: 5.9    |
|                 |                    |                              | H-D: 6       |
|                 |                    |                              | H-A: 10      |
|                 |                    |                              | MW: 546.52   |
| 4 NCI_670283    | (C_{25}H_{24}O_{2}) | -10.6                     | LogP: 4.5    |
|                 |                    |                              | H-D: 0       |
|                 |                    |                              | H-A: 2       |
|                 |                    |                              | MW: 356.45   |
| 5 NCI_127133    | (C_{27}H_{18}N_{2}O_{4}) | -8.3                  | LogP: 4.52   |
|                 |                    |                              | H-D: 3       |
|                 |                    |                              | H-A:4        |
|                 |                    |                              | MW: 434.4    |

LogP: An octanol-water partition coefficient; H-D: Hydrogen donor; H-A: Hydrogen acceptor; MW: Molecular weight.
Table 3. Analysis of the hydrogen bonds that occurred during the trajectories sampled in the MD simulations.

| Ligand            | Number of H-bonds | Details of H-bonds          | % occupancy |
|-------------------|-------------------|-----------------------------|-------------|
| NCI_61610         | 5                 | Asn24 (HD22)-O1             | 98          |
|                   |                   | Tyr114 (HN)-O               | 92          |
|                   |                   | Gly112 (HN)-O               | 88          |
|                   |                   | Thr111 (OG1)-H1             | 13          |
|                   |                   | Cys34 (HG1)-O1              | 10          |
| NCI_25457         | 3                 | Val113 (HN)-N               | 29          |
|                   |                   | Val33 (HN)-N                | 21          |
|                   |                   | Val33 (HN)-O                | 20          |
| NCI_345647_a      | 7                 | Ile11 (HN)-O4               | 39          |
|                   |                   | Ile11 (HN)-O6               | 12          |
|                   |                   | Gly112 (HN)-O1              | 18          |
|                   |                   | Val33 (HN)-O                | 17          |
|                   |                   | Gly32 (O)-O5                | 14          |
|                   |                   | Thr111 (HN)-O1              | 13          |
|                   |                   | Arg144 (HE)-O3              | 10          |
| NCI_670283        | 4                 | Thr111 (HN)-O               | 77          |
|                   |                   | Gly112 (HN)-O               | 65          |
|                   |                   | Ser110 (HN)-O               | 25          |
|                   |                   | Thr111 (HG1)-O              | 10          |
| NCI_127133        | 0                 | No H-bonds with occupancy more than 10% |

Table 4. Analysis of hydrophobic contacts during the trajectories sampled in the MD simulations.

| Ligand            | Number of interacting residues | Name of non-polar residues interactions |
|-------------------|--------------------------------|----------------------------------------|
| NCI_61610         | 8                              | Ala22, Pro25, Leu28, Val33, Pro107, Val113, Tyr114, Trp148 |
| NCI_25457         | 6                              | Ala22, Val33, Pro107, Val113, Tyr114, Trp148 |
| NCI_345647_a      | 6                              | Ile11, Val33, Ala36, Val113, Tyr114, Trp148 |
| NCI_670283        | 6                              | Ala22, Leu28, Val33, Pro107, Val113, Tyr114 |
| NCI_127133        | 3                              | Ala1, Pro2, Tyr4 |
Table 5. SASA values obtained in the simulations of apo nsP3 and complexes of it with different ligands.

|       | nsP3 | nsP3-NCI_61610 | nsP3-NCI_25457 | nsP3-NCI_345647_a | nsP3-NCI_670283 | nsP3-NCI_127133 |
|-------|------|----------------|----------------|------------------|----------------|----------------|
| Ala22 | 31.3 | 36.6           | 35.6           | 45.0             |                |                |
| Pro25 | 75.5 | 57.8           |                |                  |                |                |
| Leu28 | 102.6| 108.2          |                |                  |                | 100.8          |
| Val33 | 68.8 | 81.7           | 57.4           | 52.9             | 79.7           |                |
| Pro107| 25.9 | 20.4           | 25.2           | 24.1             |                |                |
| Val113| 129.8| 146.5          | 138.8          | 130.8            | 142.2          |                |
| Tyr114| 70.2 | 63.4           | 69.3           | 63.8             | 87.4           |                |
| Trp148| 84.0 | 88.4           | 90.2           | 95.5             |                |                |
| Ile11 | 12.6 |                |                | 25.8             |                |                |
| Ala36 | 34.0 |                |                |                  |                | 30.0           |
| Ala1  | 74.5 |                |                |                  | 81.2           |                |
| Pro2  | 37.9 |                |                |                  | 56.4           |                |
| Tyr4  | 39.2 |                |                |                  |                | 41.7           |

Supporting information

Table S1. List of poses in the docking of ADP-ribose into nsP3. RMSD refers to the heavy-atom root mean square deviation from the co-crystal structure for ADP-ribose.

| Poses | Binding affinity (kcal/mol) | RMSD (Å) |
|-------|----------------------------|----------|
| 1     | -10.2                      | 0.6      |
| 2     | -8.9                       | 8.6      |
| 3     | -8.9                       | 1.8      |
| 4     | -8.9                       | 5.5      |
| 5     | -8.6                       | 8.4      |
| 6     | -8.5                       | 4.4      |
| 7     | -8.4                       | 0.6      |
| 8     | -8.3                       | 0.6      |
| 9     | -7.8                       | 0.6      |
Table S2. Results of the top ten compounds of different runs.

| VST1 | VST2 | VST3 | VST4 | VST5 | VST6 |
|------|------|------|------|------|------|
| **Fit at the center of binding site** | **Fit at the center of binding site** | **Fit at the center of binding site** | **Fit at the center of protein** | **Fit at the prediction pocket 2** | **Fit at the prediction pocket 3** |
| Center_x = 9.7 | Center_x = 9.7 | Center_x = 9.7 | Center_x = 7.7 | Center_x = 7.7 | Center_x = 2.3 |
| Center_y = 43.0 | Center_y = 43.0 | Center_y = 45.3 | Center_y = 45.4 | Center_y = 44.6 | Center_y = -18.3 |
| Center_z = -13.2 | Center_z = -13.2 | Center_z = -5.3 | Center_z = 11.5 | Center_z = -18.3 | Center_z = -18.3 |
| **Cover site** | **Cover site** | **Cover the whole protein** | **Cover the whole protein** | **Cover site** | **Cover binding site** |
| Size 16×16×16 | Size 20×20×20 | Size 50×50×56 | Size 50×50×56 | Size 20×20×20 | Size 20×20×20 |
| 1.NCI_25457 | 1.NCI_34567_a | 1.NCI_61610 | 1.NCI_61610 | 1.NCI_127133 | 1.NCI_6070823 |
| (-10.8) | (-10.9) | (-11.1) | (-11.1) | (-8.3) | (-10.6) |
| 2.NCI_116702 | 2.NCI_37553 | 2.NCI_293778 | 2.NCI_37553 | 2.NCI_293778 | 2.NCI_319990 |
| (-10.7) | (-10.9) | (-11.0) | (-11.0) | (-8.2) | (-10.2) |
| 3.NCI_309892 | 3.NCI_25457 | 3.NCI_345647_a | 3.NCI_345647_a | 3.NCI_338042 | 3.NCI_80731 |
| (-10.3) | (-10.8) | (-10.9) | (-10.9) | (-7.6) | (-10.1) |
| 4.NCI_109451 | 4.NCI_116702 | 4.NCI_25457 | 4.NCI_25457 | 4.NCI_132232 | 4.NCI_84100_b |
| (-10.2) | (-10.7) | (-10.8) | (-10.8) | (-7.5) | (-10.1) |
| 5.NCI_127133 | 5.NCI_58052 | 5.NCI_58052 | 5.NCI_293778 | 5.NCI_310326 | 5.NCI_372278_a |
| (-10.2) | (-10.6) | (-10.6) | (-10.8) | (-7.4) | (-10.0) |
| 6.NCI_328101 | 6.NCI_127133 | 6.NCI_127133 | 6.NCI_127133 | 6.NCI_328101 | 6.NCI_84100_a |
| (-10.2) | (-10.5) | (-10.5) | (-10.7) | (-7.4) | (-9.9) |
| 7.NCI_372275_a | 7.NCI_293778 | 7.NCI_372499_b | 7.NCI_116702 | 7.NCI_69359_a | 7.NCI_97920 |
| (-10.2) | (-10.5) | (-10.3) | (-10.6) | (-7.3) | (-9.6) |
| 8.NCI_45545 | 8.NCI_670283 | 8.NCI_37553 | 8.NCI_58052 | 8.NCI_90737 | 8.NCI_58502 |
| (-10.2) | (-10.5) | (-10.3) | (-10.6) | (-7.3) | (-9.5) |
| 9.NCI_84100_b | 9.NCI_328101 | 9.NCI_309892 | 9.NCI_670283 | 9.NCI_122819_a | 9.NCI_227186_a |
| (-10.2) | (-10.4) | (-10.2) | (-10.5) | (-7.2) | (-9.4) |
| 10.NCI_37168 | 10.NCI_372499_b | 10.NCI_37168 | 10.NCI_324623 | 10.NCI_409976 | 10.NCI_293778 |
| (-10.1) | (-10.3) | (-10.2) | (-10.3) | (-7.2) | (-9.4) |

Table S3. Re-docking results for complex nsP3-NCI_61610 with different conformations of nsP3 taken from the different times of simulations at the pocket 1.

| nsP3 conformation | Binding affinity (kcal/mol) | Interaction between the inhibitor and residues of protein (with distance in Å) |
|-------------------|-----------------------------|--------------------------------------------------------------------------------|
| **At 0ns** | -11.1 | Tyr114(HH)-N=2.0, Val33(HN)-O=2.3, Asn24(HD21)-O=2.4 |
| **At 5 ns** | -10.3 | Tyr114 (OH)-H1=1.9 |
| **At 10 ns** | -11.3 | Tyr114 (OH)-H1=2.3 |
| **At 15 ns** | -10.6 | Asn24 (HD22)-O1=2.5, Ser110 (HN)-O=1.9 |
| **At 20 ns** | -11.4 | Tyr114 (OH)-H1=2.3 |
Table S4. Virtual screening results for blind docking into the pocket 1 with different conformations of nsP3 taken from the different times of simulations.

| VST-5ns | VST-10ns | VST-15ns | VST-20ns |
|---------|----------|----------|----------|
| Fit at the center of binding site | Fit at the center of binding site | Fit at the center of binding site | Fit at the center of binding site |
| Center_x = 9.7 | Center_x = 9.7 | Center_x = 9.7 | Center_x = 9.7 |
| Center_y = 43.0 | Center_y = 43.0 | Center_y = 43.0 | Center_y = 43.0 |
| Center_z = -13.2 | Center_z = -13.2 | Center_z = -13.2 | Center_z = -13.2 |
| Fit at the center of binding site | Fit at the center of binding site | Fit at the center of binding site | Fit at the center of binding site |
| Center_x = 9.7 | Center_x = 9.7 | Center_x = 9.7 | Center_x = 9.7 |
| Center_y = 43.0 | Center_y = 43.0 | Center_y = 43.0 | Center_y = 43.0 |
| Center_z = -13.2 | Center_z = -13.2 | Center_z = -13.2 | Center_z = -13.2 |
| Cover binding site | Cover binding site | Cover binding site | Cover binding site |
| Size 20×20×20 | Size 20×20×20 | Size 20×20×20 | Size 20×20×20 |
| 1.NCI_293778 | 1.NCI_293778 | 1.NCI_293778 | 1.NCI_293778 |
| (-11.6) | (-10.5) | (-10.5) | (-10.5) |
| 2.NCI_84100_b | 2.NCI_84100_b | 2.NCI_84100_b | 2.NCI_84100_b |
| (-10.7) | (-10.3) | (-10.3) | (-10.3) |
| 3.NCI_84100_a | 3.NCI_84100_a | 3.NCI_84100_a | 3.NCI_84100_a |
| (-10.6) | (-10.0) | (-10.0) | (-10.0) |
| 4.NCI_80997_b | 4.NCI_80997_b | 4.NCI_80997_b | 4.NCI_80997_b |
| (-10.5) | (-10.8) | (-10.8) | (-10.8) |
| 5.NCI_37553 | 5.NCI_37553 | 5.NCI_37553 | 5.NCI_37553 |
| (-10.4) | (-10.7) | (-10.7) | (-10.7) |
| 6.NCI_61610 | 6.NCI_61610 | 6.NCI_61610 | 6.NCI_61610 |
| (-10.3) | (-10.7) | (-10.7) | (-10.7) |
| 7.NCI_670283 | 7.NCI_670283 | 7.NCI_670283 | 7.NCI_670283 |
| (-10.2) | (-10.2) | (-10.2) | (-10.2) |
| 8.NCI_59620_a | 8.NCI_59620_a | 8.NCI_59620_a | 8.NCI_59620_a |
| (-10.2) | (-10.2) | (-10.2) | (-10.2) |
| 9.NCI_308835 | 9.NCI_308835 | 9.NCI_308835 | 9.NCI_308835 |
| (-10.2) | (-10.2) | (-10.2) | (-10.2) |
| 10.NCI_60785_a | 10.NCI_60785_a | 10.NCI_60785_a | 10.NCI_60785_a |
| (-10.2) | (-10.2) | (-10.2) | (-10.2) |
Figure S1. Structure of nsP3 with location of three binding sites at the different virtual screenings: (A) VST1; (B) VST2; (C) VST3; (D) VST4; (E) VST5; (F) VST6.